Evaxion will present new biomarker and immune data obtained from the ongoing phase 2 trial. These will further add to EVX-01’s already strong clinical data package.
Anixa Biosciences (ANIX) has entered into a letter of intent with Verdi Solutions to develop personalized and off-the-shelf peptide vaccines ...
RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.
Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback